JAMA Oncology


Publication Venue For

  • Assessment of Hospitalizations and Emergency Department Visits After Chimeric Antigen Receptor T-Cell Therapy Among Commercially Insured Patients 2022
  • Caution with Routine Use of Daratumumab for Newly Diagnosed High-Risk Multiple Myeloma - Reply.  7:635-636. 2021
  • Association of Event-Free and Distant Recurrence-Free Survival with Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer: Three-Year Follow-up Analysis for the I-SPY2 Adaptively Randomized Clinical Trial.  6:1355-1362. 2020
  • Seeing (Hearing Loss) with Fresh Eyes.  6:1335-1337. 2020
  • Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors before and after Transition of Imatinib to Generic Status.  6:542-546. 2020
  • Changes to Model Assumptions of the Cost-effectiveness of Durvalumab Therapy for Non-Small Cell Lung Cancer.  5:1066. 2019
  • Health barriers and patterns of gastric cancer care in rural central American resource-limited settings.  4:1131-1133. 2018
  • Hospital-based end-of-life care and costs for older patients with malignant brain tumors.  3:1581-1582. 2017
  • Molecular-based recursive partitioning analysis model for glioblastoma in the temozolomide era a correlative analysis based on nrg oncology RTOG 0525.  3:784-792. 2017
  • Resource use and medicare costs during lay navigation for geriatric patients with cancer.  3:817-825. 2017
  • Systemic exposure to thiopurines and risk of relapse in children with acute lymphoblastic leukemia: A children's oncology group study.  1:287-295. 2015
  • International Standard Serial Number (issn)

  • 2374-2437
  • Electronic International Standard Serial Number (eissn)

  • 2374-2445